Karolinska Development
0,999
SEK
+0,1 %
KDEV
NASDAQ Stockholm
Investment
Financials
Mindre end 1K følgere
+0,1%
+4,83%
-6,29%
-16,47%
-29,65%
-44,19%
-81,15%
-67,86%
-97,18%
Karolinska Development is a Nordic investment company in the life science sector. The company focuses on identifying medical innovations to create and develop companies that further develop such innovations into differentiated products. Karolinska Development's portfolio consists of a number of companies focused on developing treatment methods for diseases that are classified as life-threatening and serious. The largest business operations are in the Nordic market.
Læs mereMarkedsværdi
269,81 mio. SEK
Aktieomsætning
71,78 t SEK
Omsætning
2,01 mio.
EBIT %
-174,63 %
P/E
49,95
Udbytteafkast, %
-
Finanskalender
14.2
2025
Årsrapport '24
30.4
2025
Delårsrapport Q1'25
15.5
2025
Generalforsamling '25
ViserAlle indholdstyper
Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 23.8 to continue clinical development of golexanolone
Karolinska Development’s Board of Directors appoints Ben Toogood as new Chairman
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools